On Monday 7 October, the European Commission, through its Health Emergency Preparedness and Response Authority (HERA) and the European Investment Bank, signed a €20 million agreement with the French biopharmaceutical company Fabentech to help it develop broad-spectrum therapeutics to combat biological threats to public health.
HERA’s threat analysis demonstrated the importance of developing Fabentech’s technology platform which relies on the production of broad-spectrum polyclonal...